Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Postmenopausal Hormone Therapy and Breast Cancer

Postmenopausal Hormone Therapy and Breast Cancer Editorials represent the opinions EDITORIAL of the authors and JAMA and not those of the American Medical Association. Postmenopausal Hormone Therapy and Breast Cancer An Uncertain Trade-off (FDA) allows the manufacturer to claim is reduction of risk Peter B. Bach, MD, MAPP of osteoporotic fractures. That breast cancer rates in the WHI increased among N 2002, THE WOMEN’S HEALTH INITIATIVE (WHI) RAN- women receiving hormone therapy was not surprising. Epi- domized trial of placebo vs hormone therapy with es- 5 demiological and biological studies had anticipated the effect, trogen and progestin was stopped early because of evi- although the magnitude of risk was not known until the WHI, Idence of harm. Sales of combined estrogen-progestin which showed that the effect of hormone therapy on breast plummeted 32% between the period immediately before the cancer risk was about the same as the deleterious effect on study’s release and the analogous period 1 year later, as the cardiovascular health. In each case, 42 more of approxi- WHI trial had shown that hormone therapy increased a wom- mately 8000 women in the hormone therapy group than the an’s risk of breast cancer and myocardial infarction. The placebo group experienced the adverse outcome. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

Postmenopausal Hormone Therapy and Breast Cancer

JAMA , Volume 304 (15) – Oct 20, 2010

Loading next page...
 
/lp/american-medical-association/postmenopausal-hormone-therapy-and-breast-cancer-yYHqIoMEmw
Publisher
American Medical Association
Copyright
Copyright 2010 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.2010.1528
pmid
20959586
Publisher site
See Article on Publisher Site

Abstract

Editorials represent the opinions EDITORIAL of the authors and JAMA and not those of the American Medical Association. Postmenopausal Hormone Therapy and Breast Cancer An Uncertain Trade-off (FDA) allows the manufacturer to claim is reduction of risk Peter B. Bach, MD, MAPP of osteoporotic fractures. That breast cancer rates in the WHI increased among N 2002, THE WOMEN’S HEALTH INITIATIVE (WHI) RAN- women receiving hormone therapy was not surprising. Epi- domized trial of placebo vs hormone therapy with es- 5 demiological and biological studies had anticipated the effect, trogen and progestin was stopped early because of evi- although the magnitude of risk was not known until the WHI, Idence of harm. Sales of combined estrogen-progestin which showed that the effect of hormone therapy on breast plummeted 32% between the period immediately before the cancer risk was about the same as the deleterious effect on study’s release and the analogous period 1 year later, as the cardiovascular health. In each case, 42 more of approxi- WHI trial had shown that hormone therapy increased a wom- mately 8000 women in the hormone therapy group than the an’s risk of breast cancer and myocardial infarction. The placebo group experienced the adverse outcome.

Journal

JAMAAmerican Medical Association

Published: Oct 20, 2010

References